- BioLineRx Ltd.'s (NASDAQ:BLRX) product candidate for the treatment of celiac disease, BL-7010, was found to be safe and well tolerated in a Phase 1/2 clinical trial. The company expects a placebo-controlled efficacy study to commence in 2H 2015.
-
BL-7010 is an orally available co-polymer with a high affinity for gliadens, the immunogenic proteins in gluten that cause celiac disease. By sequestering gliadens, BL-7010 masks them from enzymatic degradation and prevents the formation of immunogenic peptides that trigger the immune system.